Gene Variations May Predict Response to Breast Cancer Prevention Therapies
Researchers from the Mayo Clinic have identified variants in two genes that result in a higher chance that tamoxifen or raloxifene will actually prevent breast cancer. More studies are needed, but if confirmed, women with these variants may be more likely to undergo the 5-year preventive regimen. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news
Identifying Women Most Likely To Respond To Preventive Breast Cancer Therapy
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery. "Our findings are important because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention," said James Ingle, M.D., an oncologist at Mayo Clinic. Dr... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Which Women Should Receive Preventive Breast Cancer Drugs?
A new study, published in the journal Cancer Discovery, revealed that genetic variations could be a key indicator of which women are likely and which are unlikely to benefit from tamoxifen or raloxifene for breast cancer prevention. James Ingle, M.D., an oncologist at the Mayo Clinic, who was part of the study, said that the findings are important "because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Tamoxifen: Gene Test May Predict Benefit (CME/CE)
(MedPage Today) -- Two genes may predict which women would benefit from breast cancer primary prevention with tamoxifen or raloxifene (Evista), analysis of the pivotal trials showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2013 Category: Hematology Source Type: news
Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - June 13, 2013 Category: Hospital Management Authors: Mayo Clinic Source Type: news
Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 13, 2013 Category: Databases & Libraries Authors: Mayo Clinic Source Type: news
Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - June 13, 2013 Category: Research Authors: Mayo Clinic Source Type: news
Genetic Markers Could Focus Breast Cancer ChemopreventionGenetic Markers Could Focus Breast Cancer Chemoprevention
Newly discovered genetic markers could be used to select which women would benefit most from chemoprevention with tamoxifen and raloxifene. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Newly Identified Markers May Predict Who Will Respond To Breast Cancer Prevention Therapy
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. Women who have the favorable variations of these two SNPs are more likely to respond to prevention therapy, according to this study... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Genetic variations may help identify best candidates for preventive breast cancer drugs
(Mayo Clinic) Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2013 Category: Cancer & Oncology Source Type: news
Newly identified markers may predict who will respond to breast cancer prevention therapy
(American Association for Cancer Research) Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2013 Category: Cancer & Oncology Source Type: news
Tamoxifen boost for breast cancer sufferers
Study finds that death rates fall significantly for patients who take the drug for 10 years rather than the standard fiveBreast cancer is less likely to recur if women previously treated for the disease take the drug tamoxifen for 10 years, instead of the recommended five, according to a British study. The study was a component of a larger international trial for which similar results were announced last year.Researchers estimated that, compared with taking no tamoxifen, 10 years of the drug reduces breast cancer death rates by a third in the first 10 years and by half after that. "Until now, there have been doubts whether...
Source: Guardian Unlimited Science - June 2, 2013 Category: Science Tags: The Guardian News Health Medical research Society Drugs UK news Breast cancer Science Source Type: news
First Comprehensive Analysis Reveals Long-term Effectiveness Of SERMs For Preventing Breast Cancer
Selective oestrogen receptor modulators (SERMs: tamoxifen, raloxifene, arzoxifene, and lasofoxifene) significantly reduce the risk of developing the most common type of breast cancer among women at both high and average risk of the disease* both during treatment, and for at least 5 years after stopping, according to the first comprehensive analysis of all SERM prevention trials to date published Online First in The Lancet... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 2, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Breast Cancer Drugs May Reduce Risks in Healthy High-Risk Women
Tamoxifen and raloxifene reduce the incidence of invasive breast cancer in women without cancer, but they also increase the risk of blood clots and other risks. (Source: Consultant Live)
Source: Consultant Live - April 22, 2013 Category: Primary Care Source Type: news
News From Annals Of Internal Medicine: 16 April 2013
1. Task Force Reviews Evidence for New Recommendations on Medications to Reduce Risk for Primary Breast Cancer High-risk women may derive the most benefit, least harms from preventive drug therapy Women at high risk for breast cancer may benefit most from preventive drug therapy. In 2002, the United States Preventive Services Task Force (USPSTF) recommended against routine use of tamoxifen and raloxifene for prevention of primary breast cancer for women at average risk... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
